Navigation Links
How cancer spreads: Metastatic tumor a hybrid of cancer cell and white blood cell
Date:7/2/2013

Yale Cancer Center scientists, together with colleagues at the Denver Police Crime Lab and the University of Colorado, have found evidence that a human metastatic tumor can arise when a leukocyte (white blood cell) and a cancer cell fuse to form a genetic hybrid. Their study, published in the journal PLOS ONE, may answer the question of how cancer cells travel from the primary tumor's site of origin to distant organs and tissues of the body the deadly process of metastasis.

Such a theory was first proposed as an explanation for metastasis more than a century ago. But until now, the theory was unproven in human cancer because genomic differences between cells from the same patient cannot be distinguished. To get around this problem, the researchers analyzed genomic DNA in the secondary malignancies of a patient who had a melanoma brain metastasis and had received a bone marrow transplant from his brother.

They found signature genes from both the patient and donor together in the tumor cells, providing the first evidence that leukocytes (in this case from the donor) can fuse with cancer cells and initiate a tumor.

"Our results provide the first proof in humans of a theory, proposed in 1911 by a German pathologist, that metastasis can occur when a leukocyte and cancer cell fuse and form a genetic hybrid," said corresponding author John Pawelek, research faculty in the dermatology department of the Yale School of Medicine. "This could open the way to new therapy targets, but much work needs to be done to determine how fusion occurs, the frequency of such hybrids in human cancers, and the potential role of hybrids in metastasis," he added.


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Page: 1

Related biology news :

1. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
2. Embryonic development protein active in cancer growth
3. BRG1 mutations confer resistance to hormones in lung cancer
4. Genetic variation in East Asians found to explain resistance to cancer drugs
5. Beyond the microscope: Identifying specific cancers using molecular analysis
6. Marshall University study may lead to new treatments for prostate cancer
7. Salk scientists open new window into how cancers override cellular growth controls
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Genetic abnormality offers diagnostic hope for childrens cancer
10. Protein jailbreak helps breast cancer cells live
11. Breast cancer risk gene discovery fast tracked by new technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The ... transformative for performing systematic gain-of-function studies. , This complement to loss-of-function studies, ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights ... (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital ...
Breaking Biology Technology: